Midodrin Zentiva (Midodrine Hydrochloride)

Midodrine is a pro‑drug that is converted in the body to desglymidodrine. The active metabolite binds to peripheral alpha‑1 adrenergic receptors, causing blood vessels to constrict. This vasoconstriction increases systemic vascular resistance and elevates blood pressure, especially when a person is upright.

The exact dose of Midodrin Zentiva is determined by the prescribing clinician based on the patient’s blood pressure response, age, renal function, and overall health. The prescriber will start with a low dose and adjust as needed to achieve the desired standing blood pressure.

Safety data for midodrine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Midodrin Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Midodrine is an alpha‑1 agonist that directly raises vascular tone, whereas alternatives such as fludrocortisone increase blood volume and droxidopa act as a norepinephrine pro‑drug. Midodrine often provides a rapid pressor effect but requires careful monitoring for supine hypertension, while fludrocortisone may cause fluid retention and droxidopa can have broader autonomic effects.

Midodrin Zentiva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep them away from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Midodrin Zentiva is taken orally with a full glass of water. It is usually prescribed to be taken during the day, avoiding doses within four hours of lying down, to reduce the risk of supine hypertension. Patients should follow the prescriber’s timing instructions closely.

The most serious risks include severe supine hypertension, which can lead to stroke or cardiac events, and urinary retention that may cause bladder dysfunction. Rarely, patients may experience myocardial infarction, pulmonary edema, or severe allergic reactions. Prompt medical attention is required if any of these occur.

Midodrin Zentiva is contraindicated in patients with severe organic heart disease, recent myocardial infarction, pheochromocytoma, or uncontrolled hypertension. It should also be avoided in individuals who cannot safely sit or stand upright, and in those taking certain interacting medications such as MAO inhibitors without close supervision.